Overview

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Status:
Completed
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Evolocumab